CSOWM EXAM ACTUAL 2026 QUESTIONS AND
100% CORRECT ANSWERS
Save
Terms in this set (272)
Physical Activity for At least 60 min/day of moderate to vigorous
Children/Adolescents with DM (1 & aerobic activity
2) & Pre-DM
vigorous muscle strengthening and bone
strengthening activity at least 3 days per week
Physical Activity for Adults with DM 150 min of moderate to vigorous aerobic activity
weekly (over at least 3 days)
no more than 2 consecutive days w/o activity
75 min of vigorous aerobic activity weekly (if
appropriate)
2-3 weekly sessions of resistance exercise on non
consecutive days
all adults should decrease sedentary time
(interrupt every 30 min for BG benefit)
flexibility & balance training recommended 2-3
times weekly for older adults with DM
,Potential contraindications for Retinopathy (risk of vitreous hemorrhage or
diabetes and exercise retinal detachment)
Peripheral neuropathy (exam feet, wear
protection)
Autonomic neuropathy (thorough cardiac eval)
Diabetic kidney disease (acutely increase urinate
albumin excretion) , however no specific exercise
restrictions needed.
DM and Psychosocial Care Should be integrated with a pt-centered
approach & provided to all people diagnosed
may include attitudes: expectations with meds
and outcomes, affect or mood, QOL, resources
like financial, social, emotional, and psychiatric
history
Critical times to evaluate DSMES 1. At diagnosis
2. Annually
3. When complications arise
4. When transitions in care occur
Behavior Management for Diabetics DSMES
MNT
Physical Activity
Smoking cessation
Psychosocial care
, Pharmacotherapy for type 2 DM Metformin initially (low cost)
Early insulin if evidence of catabolism,
hyperglycemia, & A1c > 10%
SGLT-2 inhibitors or GLP-1 agonist in patients with
CVD, kidney dx, or heart failure
DPP-4 inhibitors weight neutral type II DM medication
ends in -gliptin
(Januvia)
Better GI tolerability over Metformin
Type II DM Meds that cause weight Thiazolidinediones (low cost)
gain Sulfonylureas (Glyburide, Glipizide, Glimepiride)
(low cost)
Insulin
GLP-1 Agonists Liraglutide (Victoza, Saxenda)
Semaglutide (Ozempic, Wegovy)
Exenatide
Dulaglutide (Trulicity)
Injections that affect POMC neurons and cause
satiety
SGLT2 inhibitors Canagliflozin (Invokana)
Dapagliflozin (Farxiga)
Empagliflozin (Jardiance)
prevents reabsorptions of glucose as well as
water in the renal tubules
100% CORRECT ANSWERS
Save
Terms in this set (272)
Physical Activity for At least 60 min/day of moderate to vigorous
Children/Adolescents with DM (1 & aerobic activity
2) & Pre-DM
vigorous muscle strengthening and bone
strengthening activity at least 3 days per week
Physical Activity for Adults with DM 150 min of moderate to vigorous aerobic activity
weekly (over at least 3 days)
no more than 2 consecutive days w/o activity
75 min of vigorous aerobic activity weekly (if
appropriate)
2-3 weekly sessions of resistance exercise on non
consecutive days
all adults should decrease sedentary time
(interrupt every 30 min for BG benefit)
flexibility & balance training recommended 2-3
times weekly for older adults with DM
,Potential contraindications for Retinopathy (risk of vitreous hemorrhage or
diabetes and exercise retinal detachment)
Peripheral neuropathy (exam feet, wear
protection)
Autonomic neuropathy (thorough cardiac eval)
Diabetic kidney disease (acutely increase urinate
albumin excretion) , however no specific exercise
restrictions needed.
DM and Psychosocial Care Should be integrated with a pt-centered
approach & provided to all people diagnosed
may include attitudes: expectations with meds
and outcomes, affect or mood, QOL, resources
like financial, social, emotional, and psychiatric
history
Critical times to evaluate DSMES 1. At diagnosis
2. Annually
3. When complications arise
4. When transitions in care occur
Behavior Management for Diabetics DSMES
MNT
Physical Activity
Smoking cessation
Psychosocial care
, Pharmacotherapy for type 2 DM Metformin initially (low cost)
Early insulin if evidence of catabolism,
hyperglycemia, & A1c > 10%
SGLT-2 inhibitors or GLP-1 agonist in patients with
CVD, kidney dx, or heart failure
DPP-4 inhibitors weight neutral type II DM medication
ends in -gliptin
(Januvia)
Better GI tolerability over Metformin
Type II DM Meds that cause weight Thiazolidinediones (low cost)
gain Sulfonylureas (Glyburide, Glipizide, Glimepiride)
(low cost)
Insulin
GLP-1 Agonists Liraglutide (Victoza, Saxenda)
Semaglutide (Ozempic, Wegovy)
Exenatide
Dulaglutide (Trulicity)
Injections that affect POMC neurons and cause
satiety
SGLT2 inhibitors Canagliflozin (Invokana)
Dapagliflozin (Farxiga)
Empagliflozin (Jardiance)
prevents reabsorptions of glucose as well as
water in the renal tubules
